Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 951 trihydrÁt morfin-hydrochloridu - tableta s prodlouženým uvolňováním - 100mg - morfin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 951 trihydrÁt morfin-hydrochloridu - tableta s prodlouženým uvolňováním - 200mg - morfin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 951 trihydrÁt morfin-hydrochloridu - tableta s prodlouženým uvolňováním - 30mg - morfin

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

g.l. pharma gmbh, lannach array - 951 trihydrÁt morfin-hydrochloridu - tableta s prodlouženým uvolňováním - 60mg - morfin

Evropská unie - čeština - EMA (European Medicines Agency)

bristol-myers squibb pharma eeig - nivolumab, relatlimab - melanom - antineoplastic agents, monoclonal antibodies - opdualag is indicated for the first line treatment of advanced (unresectable or metastatic) melanoma in adults and adolescents 12 years of age and older with tumour cell pd l1 expression < 1%.

Evropská unie - čeština - EMA (European Medicines Agency)

ipsen pharma - cabozantinib (s)-malate - carcinoma, renal cell; carcinomas, hepatocellular - antineoplastická činidla - renal cell carcinoma (rcc)cabometyx is indicated as monotherapy for the treatment of advanced renal cell carcinoma (rcc):in treatment-naïve adults with intermediate or poor risk,in adults following prior vascular endothelial growth factor (vegf)-targeted therapy. cabometyx, in combination with nivolumab, is indicated for the first-line treatment of advanced renal cell carcinoma in adults. hepatocellular carcinoma (hcc)cabometyx is indicated as monotherapy for the treatment of hepatocellular carcinoma (hcc) in adults who have previously been treated with sorafenib.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)

Evropská unie - čeština - EMA (European Medicines Agency)

beigene ireland ltd - zanubrutinib - waldenstrom macroglobulinemia - antineoplastická činidla - brukinsa as monotherapy is indicated for the treatment of adult patients with waldenström’s macroglobulinaemia (wm) who have received at least one prior therapy, or in first line treatment for patients unsuitable for chemo-immunotherapy. brukinsa as monotherapy is indicated for the treatment of adult patients with marginal zone lymphoma (mzl) who have received at least one prior anti-cd20-based therapy. brukinsa as monotherapy is indicated for the treatment of adult patients with chronic lymphocytic leukemia (cll).

Evropská unie - čeština - EMA (European Medicines Agency)

astrazeneca ab - nirsevimab - imunitní séra a imunoglobuliny, - beyfortus is indicated for the prevention of respiratory syncytial virus (rsv) lower respiratory tract disease in neonates and infants during their first rsv season. beyfortus should be used in accordance with official recommendations.

Česká republika - čeština - SUKL (Státní ústav pro kontrolu léčiv)

potraviny pro zvlÁŠtnÍ lÉkaŘskÉ ÚČely (pzlÚ) (ČeskÁ atc skupina)